Filters








60 Hits in 1.0 sec

Activation of transcription and retrotransposition of a novel retroelement,Steamer, in neoplastic hemocytes of the molluskMya arenaria

Gloria Arriagada, Michael J. Metzger, Annette F. Muttray, James Sherry, Carol Reinisch, Craig Street, W. Ian Lipkin, Stephen P. Goff
2014 Proceedings of the National Academy of Sciences of the United States of America  
LTRs at the 5′ and 3′ ends, Gag-Pol ORF, sites for digestion by the indicated restriction enzymes, and location of the 32 P-labeled probe are indicated.  ...  The average level of expression in the diseased animals was ∼27-fold above that in the normal, and the mean levels of Steamer RNA strongly correlated with disease status (P < 0.0005.)  ... 
doi:10.1073/pnas.1409945111 pmid:25201971 pmcid:PMC4191779 fatcat:dxmel73i3ff5rk4fs7oo4kb4y4

Global Identification of Protein Post-translational Modifications in a Single-Pass Database Search

Michael R. Shortreed, Craig D. Wenger, Brian L. Frey, Gloria M. Sheynkman, Mark Scalf, Mark P. Keller, Alan D. Attie, Lloyd M. Smith
2015 Journal of Proteome Research  
The LC column was prepared by packing 20 cm of 3 μm MAGIC aqC18 beads (Bruker-Michrom, Auburn, CA) into a 100 μm i.d. capillary whose tip was pulled to ∼1 μm with a P-2000 laser puller (Sutter Instruments  ... 
doi:10.1021/acs.jproteome.5b00599 pmid:26418581 pmcid:PMC4642219 fatcat:zfnsubeb4nfmlls7ddunnlqxhy

A Single Meal Containing Raw, Crushed Garlic Influences Expression of Immunity- and Cancer-Related Genes in Whole Blood of Humans

Craig S Charron, Harry D Dawson, George P Albaugh, Patrick M Solverson, Bryan T Vinyard, Gloria I Solano-Aguilar, Aleksey Molokin, Janet A Novotny
2015 Journal of Nutrition  
Fold-change for women = 5.6 (P , 0.001) and for men = 1.5 (P = 0.32). 3 Significant sex 3 treatment interaction, P = 0.007. Fold-change for women = 2.5 (P , 0.001) and for men = 1.2 (P = 0.29).  ...  *Different from control at that time, P , 0.01.  ... 
doi:10.3945/jn.115.215392 pmid:26423732 pmcid:PMC4620724 fatcat:7rjdruc4lfbyfebb3uxyeabkbe

Early Mortality and AIDS Progression Despite High Initial Antiretroviral Therapy Adherence and Virologic Suppression in Botswana

Katherine T. Steele, Andrew P. Steenhoff, Craig W. Newcomb, Tumelo Rantleru, Rudo Nthobatsang, Gloria Lesetedi, Scarlett L. Bellamy, Jean B. Nachega, Robert Gross, Gregory P. Bisson, Nitika Pant Pai
2011 PLoS ONE  
exp (RR21)]/ [P exp (RR21)+1]} * 100 where P exp = prevalence of suboptimal adherence in the population, and RR = unadjusted relative risk of early adverse outcomes among patients with suboptimal adherence  ...  estimate the percentage of early adverse outcomes theoretically attributable to suboptimal early adherence, we calculated a population attributable risk percentage (PAR%) using the equation: PAR% = {[P  ... 
doi:10.1371/journal.pone.0020010 pmid:21698283 pmcid:PMC3115945 fatcat:sp4hirjyijhercblu2lyl24tqe

RNA sequencing of intestinal mucosa reveals novel pathways functionally linked to celiac disease pathogenesis

Maureen M. Leonard, Yu Bai, Gloria Serena, Kourtney P. Nickerson, Stephanie Camhi, Craig Sturgeon, Shu Yan, Maria R. Fiorentino, Aubrey Katz, Barbara Nath, James Richter, Matthew Sleeman (+3 others)
2019 PLoS ONE  
Our data confirmed the RNA seq analysis with IFNg (p�0.05), IL10 (p�0.05), MCM2 (p�0.005), CDC45 (p�0.001) and CXCL11 (p�0.05) significantly overexpressed in the active celiac populations as compared to  ...  The pathways with adjusted p-value < = 0.05 were reported.  ... 
doi:10.1371/journal.pone.0215132 pmid:30998704 pmcid:PMC6472737 fatcat:boca54brpbfglnqwybwosygwyq

Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B

Michael P. DiGiovanna, David F. Stern, Susan Edgerton, Gloria Broadwater, Lynn G. Dressler, Daniel R. Budman, I. Craig Henderson, Larry Norton, Edison T. Liu, Hyman B. Muss, Donald A. Berry, Daniel F. Hayes (+1 others)
2008 Journal of Clinical Oncology  
Thor Final approval of manuscript: Michael P. DiGiovanna, David F. Stern, Susan Edgerton, Gloria Broadwater, Lynn G. Dressler, Daniel R. Budman, I. Craig Henderson, Larry Norton, Edison T.  ...  Craig Henderson, Edison T. Liu, Daniel F. Hayes, Ann D. Thor Data analysis and interpretation: Michael P. DiGiovanna, David F. Stern, Gloria Broadwater, Lynn G. Dressler, Larry Norton, Hyman B.  ... 
doi:10.1200/jco.2007.13.6580 pmid:18390970 pmcid:PMC6589994 fatcat:wa4ksedrtjemfejyddywwx6kje

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Kenneth R. Carson, Scott D. Newsome, Ellen J. Kim, Nina D. Wagner-Johnston, Gloria von Geldern, Craig H. Moskowitz, Alison J. Moskowitz, Alain H. Rook, Pankaj Jalan, Alison W. Loren, Daniel Landsburg, Thomas Coyne (+6 others)
2014 Cancer  
Corresponding Author: Purpose-Brentuxiumab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate approved in 2011 for treating anaplastic large cell and Hodgkin lymphomas. The product label indicates that three BV-treated patients developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC-virus induced central nervous system infection. Prior immunosuppressive therapy and compromised immune systems were postulated risk factors. We report 5 patients who developed
more » ... ents who developed BV-associated PML, including two immunocompetent patients. Patients-Case information was obtained from clinicians (four patients) or a Food and Drug Administration database (one patient). Results-All five patients had lymphoid malignancies. Two patients with cutaneous T-cell lymphomas had not previously received chemotherapy. PML developed after a median of three BV doses (range, 2 to 6) and within a median of 7 weeks following BV initiation (range, 3 to 34 weeks). Presenting findings included aphasia, dysarthria, confusion, hemiparesis, and gait dysfunction; JC virus in cerebrospinal fluid (two patients), or CNS biopsy (three patients); and brain MRI scans with white matter abnormalities (five patients). Four patients died a median of 8 weeks (range, 6 to 16 weeks) after PML diagnosis. The sole survivor developed immune reconstitution inflammatory syndrome. Conclusion-PML can develop after a few BV doses and within weeks of BV initiation. Clinicians should be aware of this syndrome, particularly when neurologic changes develop following BV initiation. The decision to administer BV to patients with indolent cutaneous lymphomas should be based on consideration of risk-benefit profiles and of alternative options. Carson et al.
doi:10.1002/cncr.28712 pmid:24771533 pmcid:PMC4460831 fatcat:dxafm37n25gmjpu5kvfa66uzje

The Tinnitus Functional Index

Mary B. Meikle, James A. Henry, Susan E. Griest, Barbara J. Stewart, Harvey B. Abrams, Rachel McArdle, Paula J. Myers, Craig W. Newman, Sharon Sandridge, Dennis C. Turk, Robert L. Folmer, Eric J. Frederick (+9 others)
2012 Ear and Hearing  
There was a strong association between TFI means and the five levels of the tinnitus "problem" item (F[4,318] ϭ 187.0, p Ͻ 0.001).  ...  Convergent and Discriminant Validity • High Pearson cor- relations were found between TFI initial scores and those for the THI (r ϭ 0.89) and severity VAS (r ϭ 0.74, p Ͻ 0.001 for both).  ... 
doi:10.1097/aud.0b013e31822f67c0 pmid:22156949 fatcat:m6oxz76oj5balhfcdkseuj5sp4

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Kimberly J. Cocce, Jeff S. Jasper, Taylor K. Desautels, Logan Everett, Suzanne Wardell, Thomas Westerling, Robert Baldi, Tricia M. Wright, Kendall Tavares, Alex Yllanes, Yeeun Bae, Jeremy T. Blitzer (+20 others)
2019 Cell Reports  
AGR2 and LYPD3 monoclonal antibodies as produced and validated previously for treatment of xenograft tumors were provided by Craig Logsdon at MD Anderson.  ...  Statistical significance was determined using log rank test, with p = 0.011, n = 47. Hazard ratio (HR) was determined using univariate Cox proportional-hazards model (p = 0.016).  ... 
doi:10.1016/j.celrep.2019.09.032 pmid:31644911 pmcid:PMC6874102 fatcat:nd4kfddqvfeefi2go5px2jhu5i

Introduction to the SPARC Reanalysis Intercomparison Project (S-RIP) and overview of the reanalysis systems

Masatomo Fujiwara, Jonathon S. Wright, Gloria L. Manney, Lesley J. Gray, James Anstey, Thomas Birner, Sean Davis, Edwin P. Gerber, V. Lynn Harvey, Michaela I. Hegglin, Cameron R. Homeyer, John A. Knox (+23 others)
2016 Atmospheric Chemistry and Physics Discussions  
Altitude and vertical grid spacing are estimated using log-pressure altitudes (z * = H ln[p 0 /p]), where the surface pressure p 0 is set to 1000 hPa and the scale height H is set to 7 km.  ...  ): 0.3125 • 64 (hybrid σ − p) ∼ 0.266 hPa CFSv2 (CDAS-T574) NCEP CFS (2011) F440 (T574): 0.2045 • 64 (hybrid σ − p) ∼ 0.266 hPa 20CR NCEP GFS (2008) F47 (T62): 1.875 • 28 (hybrid σ − p) ∼ 2.511  ... 
doi:10.5194/acp-2016-652 fatcat:sf7kqfiv7rgsvly24e7viljalm

Introduction to the SPARC Reanalysis Intercomparison Project (S-RIP) and overview of the reanalysis systems

Masatomo Fujiwara, Jonathon S. Wright, Gloria L. Manney, Lesley J. Gray, James Anstey, Thomas Birner, Sean Davis, Edwin P. Gerber, V. Lynn Harvey, Michaela I. Hegglin, Cameron R. Homeyer, John A. Knox (+24 others)
2017 Atmospheric Chemistry and Physics  
Altitude and vertical grid spacing are estimated using log-pressure altitudes (z * = H ln[p 0 /p]), where the surface pressure p 0 is set to 1000 hPa and the scale height H is set to 7 km.  ...  ): 0.3125 • 64 (hybrid σ − p) ∼ 0.266 hPa CFSv2 (CDAS-T574) NCEP CFS (2011) F440 (T574): 0.2045 • 64 (hybrid σ − p) ∼ 0.266 hPa 20CR NCEP GFS (2008) F47 (T62): 1.875 • 28 (hybrid σ − p) ∼ 2.511  ... 
doi:10.5194/acp-17-1417-2017 fatcat:mpvjv2ngqngjflrigbvzs46kwu

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

Daniel F. Hayes, Lynn G. Dressler, Donald A. Berry, Lori J. Goldstein, Gloria Broadwater, Susan Edgerton, Ira J. Bleiweiss, Matthew J. Ellis, Jonathan F. Lara, Clifford A. Hudis, James N. Ingle, I. Craig Henderson (+5 others)
2011
OS, p=0.053) ( Table 1) .  ...  value between RFS and OS (RFS, p=0.075 vs.  ...  All Treated Patients n=3121 Patients with p53 by D07 or 1801 n=1887 Others n=1234 p-value 2 * Indicates that there were a small number of patients where these results were not known. 5-yr survival  ... 
doi:10.17615/n42e-6c96 fatcat:czel443pazfybo7tuvlponb6wi

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

Holly Brunton, Giuseppina Caligiuri, Richard Cunningham, Rosie Upstill-Goddard, Ulla-Maja Bailey, Ian M. Garner, Craig Nourse, Stephan Dreyer, Marc Jones, Kim Moran-Jones, Derek W. Wright, Viola Paulus-Hock (+34 others)
2019 Social Science Research Network  
Classical vs Squamous OCR p=<0.001  ...  **p % 0.01; ***p % 0.001.  ...  For all graphs: *p < 0.05; **p % 0.01; ***p % 0.001; ****p < 0.0001. Figure legend colors designate class: classical (pancreatic) = orange/brown; squamous = blue.  ... 
doi:10.2139/ssrn.3430714 fatcat:pel3df3vqnfi7o77oinkhcs754

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Stephan B. Dreyer, Rosie Upstill-Goddard, Viola Paulus-Hock, Clara Paris, Eirini-Maria Lampraki, Eloise Dray, Bryan Serrels, Giuseppina Caligiuri, Selma Rebus, Dennis Plenker, Zachary Galluzzo, Holly Brunton (+43 others)
2020 Gastroenterology  
We generated a novel signature of replication stress with which predicts response to ATR (P < 0.018) and WEE1 inhibitor (P < 0.029) treatment in both cell lines and human PC organoids.  ...  Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, co-segregates with response to platinum (P < 0.001) and PARP inhibitor therapy (P < 0.001) in vitro and  ...  Expression of WEE1 (P ¼ .006), CDK6 (P ¼ .02), and CDK7 (P < .001) was enriched in the squamous subtype in both PDCLs and bulk tumor ( Figure 1A) .  ... 
doi:10.1053/j.gastro.2020.09.043 pmid:33039466 pmcid:PMC8167930 fatcat:xz5thfvodvbbvlqulblmthebxa

Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease

Jeong H. Yun, Andrew Lamb, Robert Chase, Dave Singh, Margaret M. Parker, Aabida Saferali, Jørgen Vestbo, Ruth Tal-Singer, Peter J. Castaldi, Edwin K. Silverman, Craig P. Hersh, James D. Crapo (+230 others)
2018 Journal of Allergy and Clinical Immunology  
Norway: P. Bakke, Bergen. Slovenia: M. Kosnik, Golnik. Spain: A. Agusti, J. Sauleda, P. de Mallorca. Ukraine: Y. Feschenko, V. Gavrisyuk, L. Yashina, Kiev; N. Monogarova, Donetsk. United Kingdom: P.  ...  COPDGene ECLIPSE Cross-sectional Exacerbation Frequency Prospective Exacerbation Rate 1yr overall study period IRR (95% CI) p value IRR (95% CI) p value IRR (95% CI) p value Age  ... 
doi:10.1016/j.jaci.2018.04.010 pmid:29709670 pmcid:PMC5994197 fatcat:sppvssw6hjbj7krzskpkht7ujy
« Previous Showing results 1 — 15 out of 60 results